Clinical Trial News and Research

RSS

$Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS$

Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

Telik, Inc. today announced the initiation of a Phase 2 clinical trial to evaluate oral Telintra in patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome.

8 Jun 2011

Clinical-research expert moving to Stanford

Steven Goodman, MD, PhD, has worn many hats through his long and varied career, from pediatrician to biostatistician, from epidemiologist to clinical trial expert, from scientist to, well, opera singer. Admittedly, opera has been more of a hobby for him than a career path, but it does give some indication of his ability to master a wide range of subjects.

7 Jun 2011

First human implant of St. Jude Medical's Portico transcatheter aortic heart valve

St. Jude Medical, Inc., a global medical device company, today announced the first human implant of its Portico transcatheter aortic heart valve. The procedure was performed by Dr. John Webb, director of cardiac catheterization and interventional cardiology at St. Paul's Hospital in Vancouver, British Columbia.

7 Jun 2011

FDA accepts Topaz's ivermectin NDA for treatment for head lice infestations

Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application (NDA) for the use of ivermectin topical cream as a treatment for head lice infestations in children and adults.

7 Jun 2011

LLS announces four new Academic Concierge partnerships for cancer drug development

With more than 320 academic science research grants currently in its portfolio, The Leukemia & Lymphoma Society (LLS) has made it a priority to help move promising discoveries more quickly from the laboratory to clinical trial and to patients with cancer.

7 Jun 2011

Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences

Geron Corporation today announced two presentations on the company's ongoing Phase 1 clinical trial of the human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury.

7 Jun 2011

University of Perugia researcher to lead BioNanoFilter European clinical trial on Group B Strep

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today its BioNanoFilter (BNF) technology will undergo a clinical trial, led by Dr. Gian Carlo Di Renzo of the University of Perugia in Italy.

7 Jun 2011

AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis

Acorda Therapeutics, Inc. today announced an analysis of pooled clinical trial results showed patients who were responders to AMPYRA (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), regardless of either their baseline Expanded Disability Status Scale (EDSS) score or baseline walking speed.

7 Jun 2011

Unique clinical trial addresses important questions about treating AIDS-related cancers

As the world marks the 30-year anniversary of the first reporting of HIV/AIDS, now comes the realization of a new challenge for people with the incurable disease. For reasons not yet clear, people with HIV face a higher rate of cancers not usually associated with HIV. This increasing rate of "non-AIDS defining cancers" includes lung, head and neck, liver, kidney, and anal cancers, among others.

7 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

BioSante Pharmaceuticals, Inc. today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted by FDA.

7 Jun 2011

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

Merck, known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc.,, today announced the presentation of detailed results from the Phase III SUCCEED clinical trial. SUCCEED evaluated oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.

7 Jun 2011

SPI to commence enrollment in SPI-1005 clinical trial to prevent hearing loss induced by loud music

Sound Pharmaceuticals (SPI) will begin recruiting a new clinical trial testing the oral drug SPI-1005 to prevent the hearing loss induced by loud music. Exposure to loud music or noise can induce temporary and permanent auditory threshold shifts (TTS or PTS). In some people, a repeated TTS will ultimately give way to a PTS that is irreversible.

7 Jun 2011

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in gastrointestinal stromal tumors (GIST) and a Phase 1 trial of ganetespib in solid tumors evaluating a twice-weekly administration schedule.

7 Jun 2011

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported updated data from a pivotal trial of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and a phase II trial in relapsed or refractory systemic anaplastic large cell lymphoma.

7 Jun 2011

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline.

7 Jun 2011

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tragara Pharmaceuticals, Inc. announced today that apricoxib in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected patients with non-small cell lung cancer (NSCLC) who had previously failed a platinum-containing regimen for advanced disease.

7 Jun 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004.

7 Jun 2011

Testosterone spray may slow cognitive decline in post-menopausal women

Post-menopausal women have better memory after daily treatment with a testosterone spray for six months, a new preliminary study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.

7 Jun 2011

Clinical Trial News and Research

Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

Clinical-research expert moving to Stanford

First human implant of St. Jude Medical's Portico transcatheter aortic heart valve

FDA accepts Topaz's ivermectin NDA for treatment for head lice infestations

LLS announces four new Academic Concierge partnerships for cancer drug development

Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences

University of Perugia researcher to lead BioNanoFilter European clinical trial on Group B Strep

AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis

Unique clinical trial addresses important questions about treating AIDS-related cancers

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

SPI to commence enrollment in SPI-1005 clinical trial to prevent hearing loss induced by loud music

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Testosterone spray may slow cognitive decline in post-menopausal women

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer